by Suzanne Hayes | Mar 12, 2019 | Blog
This is a big “family” affair as well. As we are all aware Brexit is on our doorstep. We are all waiting for the latest news on the way we exit from the EU. There are different scenarios already on how to act and take steps as a wholesaler. But what will be the end...
by Jackie (née Heneghan) Peck | Mar 12, 2019 | Blog
brexit fmd WDA(H) Responsible Person
by Suzanne Hayes | Mar 5, 2019 | Blog
The UK Parallel Importing scheme allows for a medicinal product authorised in another EU member state to be marketed in the UK providing there is no therapeutic difference. In order to parallel import (PI) and repackage medicinal products, relevant licences would be...
by Brian Lindsay | Jan 15, 2019 | Blog, Brexit, FMD
The MHRA GDP Symposium heralds the end of the year and the opportunity to mull over any advice on Regulatory changes and Inspectorate trends. The chance for clarity and what will be expected for (very) near future changes to trading laws and status – ...
by Adel Nagy | Jan 7, 2019 | Blog, Bona Fides, Brexit, FMD
Brexit will definitely make wholesalers review their standard operating procedures (SOPs) to comply with the new laws and regulations. Will have to looking at reviewing of key procedures, documentations and policies to reflect the upcoming changes. What kind of...
by Jackie (née Heneghan) Peck | Jan 2, 2019 | Behind the scenes, Blog, Pharmacy Brands
In this day and age we would hope that medical research and clinical trials would be tightly controlled and effective. In 1994, Altman stated that we should be appalled at the money wasted in shoddy medical research where the sample size was too small to be...
